–
Статьи в журналах
-
- 2023 Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial
- Llovet Josep M., Kudo Masatoshi, Merle Philippe, Meyer Tim, Qin Shukui, Ikeda Masafumi, Xu Ruocai, Edeline Julien, Ryoo Baek-Yeol, Ren Zhenggang, Masi Gianluca, Kwiatkowski Mariusz, Lim Ho Yeong, Kim Jee Hyun, Breder Valeriy, Kumada Hiromitsu, Cheng Ann-Lii, Galle Peter R., Kaneko Shuichi, Wang Anran, Mody Kalgi, Dutcus Corina, Dubrovsky Leonid, Siegel Abby B., Finn Richard S.
- в журнале Lancet Oncology, издательство The Lancet Publishing Group (United Kingdom), том 24, № 12, с. 1399-1410 DOI